Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Correlation of the in vitro biotransformation of H3B-6527 in dog and human hepatocytes with the in vivo metabolic profile of 14C-H3B-6527 in a dog mass balance study.

Colombo F, Smith S, Lai GW, Nix D, Smith PG, Schindler J, Rioux N.

Xenobiotica. 2019 Aug 2:1-10. doi: 10.1080/00498254.2019.1643941. [Epub ahead of print]

PMID:
31305210
2.

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.

Fedoriw A, Rajapurkar SR, O'Brien S, Gerhart SV, Mitchell LH, Adams ND, Rioux N, Lingaraj T, Ribich SA, Pappalardi MB, Shah N, Laraio J, Liu Y, Butticello M, Carpenter CL, Creasy C, Korenchuk S, McCabe MT, McHugh CF, Nagarajan R, Wagner C, Zappacosta F, Annan R, Concha NO, Thomas RA, Hart TK, Smith JJ, Copeland RA, Moyer MP, Campbell J, Stickland K, Mills J, Jacques-O'Hagan S, Allain C, Johnston D, Raimondi A, Porter Scott M, Waters N, Swinger K, Boriack-Sjodin A, Riera T, Shapiro G, Chesworth R, Prinjha RK, Kruger RG, Barbash O, Mohammad HP.

Cancer Cell. 2019 Jul 8;36(1):100-114.e25. doi: 10.1016/j.ccell.2019.05.014. Epub 2019 Jun 27.

PMID:
31257072
3.

Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).

Rioux N, Smith S, Korpal M, O'Shea M, Prajapati S, Zheng GZ, Warmuth M, Smith PG.

Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160. doi: 10.1007/s00280-018-3716-3. Epub 2018 Nov 1.

PMID:
30386887
4.

Porphyrin-Based SOD Mimic MnTnBu OE -2-PyP5+ Inhibits Mechanisms of Aortic Valve Remodeling in Human and Murine Models of Aortic Valve Sclerosis.

Anselmo W, Branchetti E, Grau JB, Li G, Ayoub S, Lai EK, Rioux N, Tovmasyan A, Fortier JH, Sacks MS, Batinic-Haberle I, Hazen SL, Levy RJ, Ferrari G.

J Am Heart Assoc. 2018 Oct 16;7(20):e007861. doi: 10.1161/JAHA.117.007861.

5.

Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers.

Rioux N, Kim A, Nix D, Bowser T, Warmuth M, Smith PG, Schindler J.

Cancer Chemother Pharmacol. 2019 Jan;83(1):91-96. doi: 10.1007/s00280-018-3708-3. Epub 2018 Oct 27.

PMID:
30368584
6.

Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.

Puyang X, Furman C, Zheng GZ, Wu ZJ, Banka D, Aithal K, Agoulnik S, Bolduc DM, Buonamici S, Caleb B, Das S, Eckley S, Fekkes P, Hao MH, Hart A, Houtman R, Irwin S, Joshi JJ, Karr C, Kim A, Kumar N, Kumar P, Kuznetsov G, Lai WG, Larsen N, Mackenzie C, Martin LA, Melchers D, Moriarty A, Nguyen TV, Norris J, O'Shea M, Pancholi S, Prajapati S, Rajagopalan S, Reynolds DJ, Rimkunas V, Rioux N, Ribas R, Siu A, Sivakumar S, Subramanian V, Thomas M, Vaillancourt FH, Wang J, Wardell S, Wick MJ, Yao S, Yu L, Warmuth M, Smith PG, Zhu P, Korpal M.

Cancer Discov. 2018 Sep;8(9):1176-1193. doi: 10.1158/2159-8290.CD-17-1229. Epub 2018 Jul 10.

7.

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.

Thomenius MJ, Totman J, Harvey D, Mitchell LH, Riera TV, Cosmopoulos K, Grassian AR, Klaus C, Foley M, Admirand EA, Jahic H, Majer C, Wigle T, Jacques SL, Gureasko J, Brach D, Lingaraj T, West K, Smith S, Rioux N, Waters NJ, Tang C, Raimondi A, Munchhof M, Mills JE, Ribich S, Porter Scott M, Kuntz KW, Janzen WP, Moyer M, Smith JJ, Chesworth R, Copeland RA, Boriack-Sjodin PA.

PLoS One. 2018 Jun 1;13(6):e0197372. doi: 10.1371/journal.pone.0197372. eCollection 2018.

8.

Serotonin receptor 2B signaling with interstitial cell activation and leaflet remodeling in degenerative mitral regurgitation.

Driesbaugh KH, Branchetti E, Grau JB, Keeney SJ, Glass K, Oyama MA, Rioux N, Ayoub S, Sacks MS, Quackenbush J, Levy RJ, Ferrari G.

J Mol Cell Cardiol. 2018 Feb;115:94-103. doi: 10.1016/j.yjmcc.2017.12.014. Epub 2017 Dec 30.

9.

Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma.

Drew AE, Moradei O, Jacques SL, Rioux N, Boriack-Sjodin AP, Allain C, Scott MP, Jin L, Raimondi A, Handler JL, Ott HM, Kruger RG, McCabe MT, Sneeringer C, Riera T, Shapiro G, Waters NJ, Mitchell LH, Duncan KW, Moyer MP, Copeland RA, Smith J, Chesworth R, Ribich SA.

Sci Rep. 2017 Dec 21;7(1):17993. doi: 10.1038/s41598-017-18446-z.

10.

H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.

Joshi JJ, Coffey H, Corcoran E, Tsai J, Huang CL, Ichikawa K, Prajapati S, Hao MH, Bailey S, Wu J, Rimkunas V, Karr C, Subramanian V, Kumar P, MacKenzie C, Hurley R, Satoh T, Yu K, Park E, Rioux N, Kim A, Lai WG, Yu L, Zhu P, Buonamici S, Larsen N, Fekkes P, Wang J, Warmuth M, Reynolds DJ, Smith PG, Selvaraj A.

Cancer Res. 2017 Dec 15;77(24):6999-7013. doi: 10.1158/0008-5472.CAN-17-1865.

11.

Bilateral internal mammary artery Y construct with multiple sequential grafting improves survival compared to bilateral internal mammary artery with additional vein grafts: 10-year experience at 2 different institutions†.

Glineur D, Etienne PY, Kuschner CE, Shaw RE, Ferrari G, Rioux N, Papadatos S, Brizzio M, Mindich B, Zapolanski A, Grau JB.

Eur J Cardiothorac Surg. 2017 Feb 1;51(2):368-375. doi: 10.1093/ejcts/ezw282.

PMID:
28186272
12.

Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.

Fader LD, Bailey M, Beaulieu E, Bilodeau F, Bonneau P, Bousquet Y, Carson RJ, Chabot C, Coulombe R, Duan J, Fenwick C, Garneau M, Halmos T, Jakalian A, James C, Kawai SH, Landry S, LaPlante SR, Mason SW, Morin S, Rioux N, Simoneau B, Surprenant S, Thavonekham B, Thibeault C, Trinh T, Tsantrizos Y, Tsoung J, Yoakim C, Wernic D.

ACS Med Chem Lett. 2016 Jun 9;7(8):797-801. doi: 10.1021/acsmedchemlett.6b00194. eCollection 2016 Aug 11.

13.

CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice.

Poissonnier A, Sanséau D, Le Gallo M, Malleter M, Levoin N, Viel R, Morere L, Penna A, Blanco P, Dupuy A, Poizeau F, Fautrel A, Seneschal J, Jouan F, Ritz J, Forcade E, Rioux N, Contin-Bordes C, Ducret T, Vacher AM, Barrow PA, Flynn RJ, Vacher P, Legembre P.

Immunity. 2016 Jul 19;45(1):209-23. doi: 10.1016/j.immuni.2016.06.028.

14.

Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666.

Duncan KW, Rioux N, Boriack-Sjodin PA, Munchhof MJ, Reiter LA, Majer CR, Jin L, Johnston LD, Chan-Penebre E, Kuplast KG, Porter Scott M, Pollock RM, Waters NJ, Smith JJ, Moyer MP, Copeland RA, Chesworth R.

ACS Med Chem Lett. 2015 Dec 2;7(2):162-6. doi: 10.1021/acsmedchemlett.5b00380. eCollection 2016 Feb 11.

15.

Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.

Mitchell LH, Boriack-Sjodin PA, Smith S, Thomenius M, Rioux N, Munchhof M, Mills JE, Klaus C, Totman J, Riera TV, Raimondi A, Jacques SL, West K, Foley M, Waters NJ, Kuntz KW, Wigle TJ, Scott MP, Copeland RA, Smith JJ, Chesworth R.

ACS Med Chem Lett. 2015 Aug 27;7(2):134-8. doi: 10.1021/acsmedchemlett.5b00272. eCollection 2016 Feb 11.

16.

Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.

Rioux N, Waters NJ.

Drug Metab Dispos. 2016 Jul;44(7):934-43. doi: 10.1124/dmd.115.068031. Epub 2016 Mar 2. Review.

PMID:
26936973
17.

Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor.

Rioux N, Duncan KW, Lantz RJ, Miao X, Chan-Penebre E, Moyer MP, Munchhof MJ, Copeland RA, Chesworth R, Waters NJ.

Xenobiotica. 2016;46(3):268-77.

PMID:
26294260
18.

Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound.

Mitchell LH, Drew AE, Ribich SA, Rioux N, Swinger KK, Jacques SL, Lingaraj T, Boriack-Sjodin PA, Waters NJ, Wigle TJ, Moradei O, Jin L, Riera T, Porter-Scott M, Moyer MP, Smith JJ, Chesworth R, Copeland RA.

ACS Med Chem Lett. 2015 Apr 6;6(6):655-9. doi: 10.1021/acsmedchemlett.5b00071. eCollection 2015 Jun 11.

19.

EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.

Campbell JE, Kuntz KW, Knutson SK, Warholic NM, Keilhack H, Wigle TJ, Raimondi A, Klaus CR, Rioux N, Yokoi A, Kawano S, Minoshima Y, Choi HW, Porter Scott M, Waters NJ, Smith JJ, Chesworth R, Moyer MP, Copeland RA.

ACS Med Chem Lett. 2015 Mar 4;6(5):491-5. doi: 10.1021/acsmedchemlett.5b00037. eCollection 2015 May 14.

20.

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.

Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, Rioux N, Munchhof MJ, Jin L, Jacques SL, West KA, Lingaraj T, Stickland K, Ribich SA, Raimondi A, Scott MP, Waters NJ, Pollock RM, Smith JJ, Barbash O, Pappalardi M, Ho TF, Nurse K, Oza KP, Gallagher KT, Kruger R, Moyer MP, Copeland RA, Chesworth R, Duncan KW.

Nat Chem Biol. 2015 Jun;11(6):432-7. doi: 10.1038/nchembio.1810. Epub 2015 Apr 27.

PMID:
25915199
21.

Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652.

Rioux N, Mitchell LH, Tiller P, Plant K, Shaw J, Frost K, Ribich S, Moyer MP, Copeland RA, Chesworth R, Waters NJ.

Drug Metab Dispos. 2015 Jul;43(7):936-43. doi: 10.1124/dmd.115.064014. Epub 2015 Apr 17.

PMID:
25887455
22.

Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor.

Fenwick C, Amad M, Bailey MD, Bethell R, Bös M, Bonneau P, Cordingley M, Coulombe R, Duan J, Edwards P, Fader LD, Faucher AM, Garneau M, Jakalian A, Kawai S, Lamorte L, LaPlante S, Luo L, Mason S, Poupart MA, Rioux N, Schroeder P, Simoneau B, Tremblay S, Tsantrizos Y, Witvrouw M, Yoakim C.

Antimicrob Agents Chemother. 2014 Jun;58(6):3233-44. doi: 10.1128/AAC.02719-13. Epub 2014 Mar 24.

23.

Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma.

Saroufim A, Messai Y, Hasmim M, Rioux N, Iacovelli R, Verhoest G, Bensalah K, Patard JJ, Albiges L, Azzarone B, Escudier B, Chouaib S.

Br J Cancer. 2014 Apr 2;110(7):1778-84. doi: 10.1038/bjc.2014.71. Epub 2014 Mar 4.

24.

Epicardial surgical ligation of the left atrial appendage is safe, reproducible, and effective by transesophageal echocardiographic follow-up.

Zapolanski A, Johnson CK, Dardashti O, O'Keefe RM, Rioux N, Ferrari G, Shaw RE, Brizzio ME, Grau JB.

Innovations (Phila). 2013 Sep-Oct;8(5):371-5. doi: 10.1097/IMI.0000000000000022.

PMID:
24346587
25.

Blood transfusion in cardiac surgery does increase the risk of 5-year mortality: results from a contemporary series of 1714 propensity-matched patients.

Shaw RE, Johnson CK, Ferrari G, Brizzio ME, Sayles K, Rioux N, Zapolanski A, Grau JB.

Transfusion. 2014 Apr;54(4):1106-13. doi: 10.1111/trf.12364. Epub 2013 Aug 2.

PMID:
23909477
26.

Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model.

Rioux N, Bellavance E, Bourg S, Garneau M, Ribadeneira MD, Duan J.

Biopharm Drug Dispos. 2013 Oct;34(7):396-401. doi: 10.1002/bdd.1855. Epub 2013 Aug 14.

PMID:
23873286
27.

Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype.

Beaulieu PL, Coulombe R, Duan J, Fazal G, Godbout C, Hucke O, Jakalian A, Joly MA, Lepage O, Llinàs-Brunet M, Naud J, Poirier M, Rioux N, Thavonekham B, Kukolj G, Stammers TA.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4132-40. doi: 10.1016/j.bmcl.2013.05.037. Epub 2013 May 23.

PMID:
23768906
28.

Balancing the benefits and risks of blood transfusions in patients undergoing cardiac surgery: a propensity-matched analysis.

Shaw RE, Johnson CK, Ferrari G, Zapolanski A, Brizzio M, Rioux N, Edara S, Sperling J, Grau JB.

Interact Cardiovasc Thorac Surg. 2013 Jul;17(1):96-102. doi: 10.1093/icvts/ivt124. Epub 2013 Mar 28.

29.

A strategy to reduce biliary clearance in early drug discovery.

Rioux N, Bellavance E, Poirier H, Dupuis M, Garneau M, Ribadeneira MD, Duan J.

J Pharmacol Toxicol Methods. 2013 Nov-Dec;68(3):346-8. doi: 10.1016/j.vascn.2013.03.003. Epub 2013 Mar 19.

PMID:
23518065
30.

A membrane vesicle-based assay to enable prediction of human biliary excretion.

Colombo F, Poirier H, Rioux N, Montecillo MA, Duan J, Ribadeneira MD.

Xenobiotica. 2013 Oct;43(10):915-9. doi: 10.3109/00498254.2013.769649. Epub 2013 Feb 12.

PMID:
23402371
31.

A simplified approach to predict CYP3A-mediated drug-drug interactions at early drug discovery: validation with clinical data.

Rioux N, Batonga J, Colombo F, Massé J, Zouki C, Ribadeneira MD, Duan J, Bethell RC.

Xenobiotica. 2013 Jul;43(7):592-7. doi: 10.3109/00498254.2012.751141. Epub 2012 Dec 17.

PMID:
23244592
32.

A high throughput in vitro mrp2 assay to predict in vivo biliary excretion.

Colombo F, Armstrong C, Duan J, Rioux N.

Xenobiotica. 2012 Feb;42(2):157-63. doi: 10.3109/00498254.2011.614021. Epub 2011 Oct 2.

PMID:
21961530
33.

Regulatory T cells in kidney allograft infiltrates correlate with initial inflammation and graft function.

Taflin C, Nochy D, Hill G, Frouget T, Rioux N, Vérine J, Bruneval P, Glotz D.

Transplantation. 2010 Jan 27;89(2):194-9. doi: 10.1097/TP.0b013e3181c3ca11.

PMID:
20098282
34.

Systemic light chain amyloidosis and Sjogren syndrome: an uncommon association.

Perlat A, Decaux O, Gervais R, Rioux N, Grosbois B.

Amyloid. 2009;16(3):181-2. doi: 10.1080/13506120903090692.

PMID:
19636991
35.

[Pseudomalignant endoscopic appearance in hyperplastic polyp at esophagogastric junction: case report].

Salihoun M, Stock N, Alexandre JL, Rioux N, Bretagne JF, Heresbach D.

Gastroenterol Clin Biol. 2008 Apr;32(4):370-3. doi: 10.1016/j.gcb.2007.11.015. Epub 2008 Apr 9. French.

36.

[Pyoderma gangrenosum and aseptic pyosalpinx in a pregnant patient].

Dinulescu M, Vigy P, Droitcourt C, Adamski H, Rioux N, Bretagne JF, Chevrant-Breton J.

Ann Dermatol Venereol. 2007 Feb;134(2):179-80. French. No abstract available.

PMID:
17375021
37.

The challenges of implementing an electronic medical record system in a long-term care facility.

Fournier D, Gosselin D, Rioux N.

Geriatr Nurs. 2006 Jan-Feb;27(1):28-30. No abstract available.

PMID:
16528841
38.

Quantification of the expression and inducibility of 12 rat cytochrome P450 isoforms by quantitative RT-PCR.

Caron E, Rioux N, Nicolas O, Lebel-Talbot H, Hamelin BA.

J Biochem Mol Toxicol. 2005;19(6):368-78.

PMID:
16421897
39.

Implementing an EHR system.

Fournier D, Gosselin D, Rioux N.

Provider. 2004 Dec;30(12):37-8, 40. No abstract available.

PMID:
15675631
40.

[Renal vascular lesions and the occurrence of hypertension in patients with IgA nephropathy].

Boulahrouz R, Stanescu C, Charasse C, Ang KS, Le Cacheux P, Leonetti F, Rioux N, Ramee MP, Simon P.

Arch Mal Coeur Vaiss. 2004 Jul-Aug;97(7-8):782-5. French.

PMID:
15506066
41.

Epidemiologic data of primary glomerular diseases in western France.

Simon P, Ramee MP, Boulahrouz R, Stanescu C, Charasse C, Ang KS, Leonetti F, Cam G, Laruelle E, Autuly V, Rioux N.

Kidney Int. 2004 Sep;66(3):905-8.

42.

[Selective COX-2 inhibitor-associated colitis: two case reports].

d'Halluin PN, Turlin B, Polard E, Dinasquet M, Pagenault M, Rioux N, Gosselin M, Bretagne JF, Heresbach D.

Gastroenterol Clin Biol. 2003 Oct;27(10):932-5. Review. French.

43.

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone modulation of cytokine release in U937 human macrophages.

Rioux N, Castonguay A.

Cancer Immunol Immunother. 2001 Feb;49(12):663-70.

PMID:
11258792
45.
46.

Induction of COX expression by a tobacco carcinogen: implication in lung cancer chemoprevention.

Rioux N, Castonguay A.

Inflamm Res. 1999 Dec;48 Suppl 2:S136-7. No abstract available.

PMID:
10667852
47.
48.

Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents.

Rioux N, Castonguay A.

Carcinogenesis. 1998 Aug;19(8):1393-400.

PMID:
9744535
49.

Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone).

Malkinson AM, Koski KM, Dwyer-Nield LD, Rice PL, Rioux N, Castonguay A, Ahnen DJ, Thompson H, Pamukcu R, Piazza GA.

Carcinogenesis. 1998 Aug;19(8):1353-6.

PMID:
9744528
50.

Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis.

Castonguay A, Rioux N, Duperron C, Jalbert G.

Exp Lung Res. 1998 Jul-Aug;24(4):605-15.

PMID:
9659586

Supplemental Content

Support Center